Jennifer A Wargo
Overview
Explore the profile of Jennifer A Wargo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
32484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Massara M, Ballabio M, Dolfi B, Morad G, Wischnewski V, Lamprou E, et al.
iScience
. 2025 Feb;
28(2):111874.
PMID: 39995854
Brain metastases (BrMs) are the most common brain tumors in patients and are associated with poor prognosis. Investigating the systemic and environmental factors regulating BrM biology represents an important strategy...
2.
Ballerini M, Galie S, Tyagi P, Catozzi C, Raji H, Nabinejad A, et al.
Nat Biomed Eng
. 2025 Feb;
PMID: 39939548
Patient responses to immune checkpoint inhibitors can be influenced by the gastrointestinal microbiome. Mouse models can be used to study microbiome-host crosstalk, yet their utility is constrained by substantial anatomical,...
3.
Rosario S, Long M, Chilakapati S, Gomez E, Battaglia S, Singh P, et al.
Nat Commun
. 2024 Dec;
15(1):10609.
PMID: 39638782
Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase...
4.
Farias R, Jiang Y, Levy E, Hwang C, Wang J, Burton E, et al.
BMC Cancer
. 2024 Dec;
24(1):1493.
PMID: 39633321
Background: Gut microbiome modulation is a promising strategy for enhancing the response to immune checkpoint blockade (ICB). Fecal microbiota transplant studies have shown positive signals of improved outcomes in both...
5.
Johnston C, Wargo J
Trends Immunol
. 2024 Nov;
45(12):931-933.
PMID: 39603891
In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to...
6.
Angelidakis G, Chemaly R, Sahasrabhojane P, Morado-Aramburo O, Jiang Y, Bhatti M, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340100
Patients undergoing immune effector cell therapy (IECT) are at high risk for infections. We assessed seropositivity against pneumococcus, tetanus, and diphtheria in patients before and after IECT and the patients'...
7.
Rahal Z, Liu Y, Peng F, Yang S, Jamal M, Sharma M, et al.
Cancer Immunol Res
. 2024 Sep;
12(12):1736-1752.
PMID: 39269772
Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely coupled with tobacco-associated lung...
8.
Hayase E, Hayase T, Mukherjee A, Stinson S, Jamal M, Ortega M, et al.
Cell Host Microbe
. 2024 Aug;
32(9):1621-1636.e6.
PMID: 39214085
Acute lower gastrointestinal GVHD (aLGI-GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation. Although the intestinal microbiota is associated with the incidence of aLGI-GVHD, how the intestinal microbiota...
9.
Boe R, Triandafillou C, Lazcano R, Wargo J, Raj A
bioRxiv
. 2024 Jul;
PMID: 39005406
Resistance to cancer therapy is driven by both cell-intrinsic and microenvironmental factors. Previous work has revealed that multiple resistant cell fates emerge in melanoma following treatment with targeted therapy and...
10.
Friedman A, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper Z, Piris A, et al.
PLoS One
. 2024 Jul;
19(7):e0306658.
PMID: 38950005
[This corrects the article DOI: 10.1371/journal.pone.0140310.].